Victor A. Chow - Concepedia

Author

Victor A. Chow

Fred Hutch Cancer Center ORCID

Also Known As

V. Chow, Victor A Chow, Victor A. Chow, Victor Chow

Publications

875

Citations

H-Index

Concepts

All Affiliations

Fred Hutch Cancer Center University of Washington Harvard University Seattle Cancer Care Alliance Northwestern University

About

Victor A. Chow is an author at Fred Hutch Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	69
2	Cellular Therapies	2	2	34
3	Health Sciences	1	1	14
4	Cell Biology	1	1	20
5	Immunology	1	1	20

Victor A. Chow

Publications

511

Citations

H-Index

Page 1

	Year	Citations
Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients Filippo Milano, Steven A. Pergam, Hu Xie, Blood	2011	105
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant Michael Scordo, Trent Wang, Kwang Woo Ahn, JAMA Oncology	2021	74
Amino Acids and mTOR Mediate Distinct Metabolic Checkpoints in Mammalian G1 Cell Cycle Mahesh Saqcena, Deepak Menon, Deven Patel, PLoS ONE	2013	71
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL Jordan Gauthier, Nicolas Gazeau, Alexandre V. Hirayama, Blood	2022	48
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma Jennifer L. Crombie, Loretta J. Nastoupil, Robert Redd, Blood Advances Lymphoid NeoplasiaTranslational MedicineAxicabtagene CiloleucelMedicineAdult Patients	2021	35
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy Victor A. Chow, Ajay K. Gopal, David G. Maloney, Blood	2018	26
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy Victor A. Chow, Ajay K. Gopal, Jordan Gauthier, Blood Advances Hematological MalignancyLymphoid NeoplasiaCell-based TherapiesCell TherapyOncology	2020	20
Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy Nicolas Gazeau, Pere Barba, Gloria Iacoboni, Blood	2021	18
Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study Lorenzo Iovino, Qian Wu, Jenna Voutsinas, Journal of Cellular and Molecular Medicine	2022	16
Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Blood	2023	15

Page 1